High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.
1992; BMJ; Volume: 55; Issue: 1 Linguagem: Inglês
10.1136/jnnp.55.1.60
ISSN1468-330X
AutoresS. Jann, Silvia Beretta, Maurizio Moggio, Laura Adobbati, Gaia Pellegrini,
Tópico(s)Muscle and Compartmental Disorders
ResumoTwo patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.
Referência(s)